Enzolytics Inc
Change company Symbol lookup
Select an option...
ENZC Enzolytics Inc
GREE Greenidge Generation Holdings Inc
MLM Martin Marietta Materials Inc
ERESW East Resources Acquisition Equity Warrant Exp 1st July 2027 *W EXP 07/01/2027
NRAC Noble Rock Acquisition Corp
DCGO DocGo Inc
VELOW Velocity Acquisition Equity Warrant Exp 24 Feb 2028 *W EXP 02/24/2028
MRC MRC Global Inc
BAC Bank of America Corp
BKR Baker Hughes Co
Go

Company profile

Enzolytics, Inc. is a drug development biotechnology company. The Company is engaged in the commercialization of its proteins for the treatment of debilitating infectious diseases. The Company is focused in developing monoclonal antibody therapy and treating infectious diseases. It has anti-HIV therapeutics and a methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The Company has clinically tested anti-HIV therapeutics. The Company has developed a cell line that produces fully human monoclonal antibodies that target and neutralizes the HIV virus. The Company has also created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus, and diphtheria. The Company is testing these antibodies to prepare them for use as therapies against these diseases.

Closing Price
$0.0737
Day's Change
0.0027 (3.73%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.0821
Day's Low
0.0701
Volume
(Light)
Volume:
5,325,554

10-day average volume:
9,319,420
5,325,554

DexCom Inc. Stock Underperforms Tuesday When Compared To Competitors

4:51 pm ET January 4, 2022 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of DexCom Inc. (DXCM) slipped 1.64% to $512.27 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.59% to 36,799.65 and the S&P 500 Index falling 0.06% to 4,793.54. This was the stock's third consecutive day of losses. DexCom Inc. closed $147.18 below its 52-week high ($659.45), which the company achieved on November 18th.

The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Johnson & Johnson (JNJ) fell 0.27% to $171.08, Abbott Laboratories (ABT) fell 2.35% to $135.77, and Medtronic PLC (MDT) rose 0.27% to $106.39. Trading volume (753,772) eclipsed its 50-day average volume of 721,616.

Data source: Dow Jones Market Data, FactSet. Data compiled Janurary 4, 2022.

-MarketWatch Automation

	

(END) Dow Jones Newswires

January 04, 2022 16:51 ET (21:51 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.